The obesity treatment market continues to grow with the launch of new products. The size of the new market has expanded by more than 60% over the past four years. According to IQVIA, a pharmaceutical research institute, on the 29th, the size of the obesity treatment market in the first quarter was 35.7 billion won, up 11.3% year-on-year.

The domestic obesity treatment market is continuously on the rise, growing 66.4% in four years from 21.4 billion won in the first quarter of 2018.

The recent growth of the obesity treatment market is driven by new products Saxenda and Qsymia. Saxenda, which was released in Korea in 2018, is the world's first obesity treatment approved as a GLP-1 (Glucago